Pegbio's new drug approval detonates the GLP-1 track, leading domestically produced flagship product aiming at a trillion-dollar market.

Today, PAG Biotech's GLP-1 new drug Pagdakang has been approved by the National Medical Products Administration for market entry, accurately targeting the billion-dollar market of 140 million diabetes patients in China. Although there are many players in the GLP-1 field, current therapies are limited by gastrointestinal side effects and complexity of use, leading to poor patient compliance. Pagdakang has built differentiation barriers with precise PEGylation technology, and its Phase III clinical data has been published in the "Lancet" sub-journal: monotherapy achieved sustained glucose stability for 52 weeks, with a gastrointestinal adverse event rate of less than 7%, and also has a "four high co-management" effect on blood pressure, blood lipids, and body fat regulation, significantly improving compliance with the convenient injection device. Several top clinical experts in China believe that it is likely to become the preferred option for type 2 diabetes. International giants have verified the value of the track, with Lilly's stock price soaring more than 10 times in the past five years, approaching a market value of close to a trillion, driving the expected size of the GLP-1 track market from $500 billion to $1.5 trillion.